Biodesix, Inc.
6.54-0.01 (-0.15%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · BDSX · USD
Key Stats
Market Cap
52.32MP/E (TTM)
-Basic EPS (TTM)
-5.20Dividend Yield
0%Recent Filings
8-K
Biodesix regains Nasdaq compliance
Biodesix regained Nasdaq compliance on September 26, 2025, after its common stock closed above $1.00 per share for ten consecutive business days, resolving a March 24, 2025, deficiency notice. This lifts the delisting threat, stabilizing the company's market position. Compliance restored. No further actions required.
8-K
Biodesix completes 1:20 reverse split
Biodesix executed a one-for-twenty reverse stock split on September 15, 2025, consolidating shares to meet Nasdaq listing standards while preserving stockholder value. The board approved the ratio on September 4, following stockholder authorization in May. No fractional shares issued; cash payments cover fractions based on prior closing price. It also eliminated its Series A preferred stock series on September 12, 2025. Trading resumes split-adjusted under new CUSIP 09075X207.
8-K
Biodesix enacts 1-for-20 split
Biodesix approved a one-for-twenty reverse stock split on September 11, 2025, effective September 15, slashing outstanding shares from 156 million to about 8 million. This move, greenlit by shareholders in May, keeps the trading symbol BDSX on Nasdaq but adjusts equity awards and warrants proportionally. Cash replaces fractional shares. Yet stock price effects remain uncertain amid market risks.
10-Q
Q2 FY2025 results
Biodesix posted Q2 revenue of $20.0M, up 12% y/y from $17.9M, with diagnostic tests climbing 8% to $17.9M on higher volumes while development services surged 53% to $2.1M. Gross margin hit 80%, edging up 1.5 points y/y as workflow tweaks trimmed costs per test. Yet operating loss widened 18% to $9.7M amid 14% higher sales and marketing spend to fuel adoption, pushing net loss to $11.5M—6% worse y/y, mainly from interest on the $50M Perceptive debt drawn fully in May at ~13.3% rate. Cash dipped to $20.7M after $15.2M operating burn, but the term loan bolsters liquidity through 2027 maturity. Revenue momentum builds steadily. Nasdaq bid price compliance hangs in the balance.
8-K
Biodesix Q2 revenue up 12%
Biodesix reported Q2 2025 revenue of $20.0 million, up 12% from last year, with lung diagnostic testing at $17.9 million (up 8%) and development services surging 53% to $2.1 million. Gross margins hit 80%, a 150-basis point gain, while sales team expansion to 74 reps fueled primary care orders over 100% higher. Yet net loss widened to $11.5 million. The company reaffirms FY2025 revenue guidance of $80-85 million and eyes Adjusted EBITDA positivity in Q4.
IPO
Website
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
181.52-2.69
BIAF
bioAffinity Technologies, Inc.
2.48-0.01
CODX
Co-Diagnostics, Inc.
0.49-0.08
DGX
Quest Diagnostics Incorporated
174.78-3.50
EXAS
Exact Sciences Corporation
62.74-0.56
IDXG
Interpace Biosciences, Inc.
1.10-0.04
IDXX
IDEXX Laboratories, Inc.
627.66-6.70
LH
Labcorp Holdings Inc.
248.14-11.55
PSNL
Personalis, Inc.
9.55-0.20
VCYT
Veracyte, Inc.
35.41-0.19